


Radisson SAS Falconer Hotel
Falkoner Alle 9, Frederiksberg
☎ +45 3815 8001
www.radissonsas.com



Scandinavian Neuro-Oncology Society Meeting

October 11-12, 2007

Radisson SAS Falconer Hotel
Falkoner Alle 9, Frederiksberg, Denmark



Sponsored by Grants from
Schering-Plough

THURSDAY

13.10-17.30	SCIENTIFIC PROGRAMME	PRESENTER	CHAIRMAN
12.00-13.00	Arrival and registration - Sandwiches will be served		
13.00-13.10	Welcome. By Hans Skovgaard Poulsen		
13.10-13.45	Lecture 1 Cancer stem cells in gliomas, controversies and insights.	Rolf Bjerkvig	
13.45-14.45	Session 1 Basic research		
13.45-14.05	Localisation and clinical relevance of the putative CD133 positive tumor stem cell niche in glioblastoma.	Bjarne Winther Kristensen	
14.05-14.25	The LRIG protein family: Regulation of ERBB2 and PDGF receptors, their expression by myelinating cells, and prognostic significance in Oligodendroglioma.	Camilla Holmlund	Roger Henriksson Marie-Thérèse Stockhausen
14.25-14.45	The GFP-expressing nod/scid mouse: A novel immunodeficient animal model to study host-tumor interactions.	Simone P. Niclou	
14.45-15.15	Coffee break		
15.15-16.15	Lecture II Defective Receptor Signaling in Glioma. Discussion	Professor Webster Cavenee, San Diego	
16.15-17.15	Session II Preclinical research.		
16.15-16.35	In Vitro Effects of cetuximab on EGFR and Downstream Mediators.	Benedikte Hasselbalch	
16.35-16.55	Treatment with the receptor tyrosine kinase inhibitor ZD6474 alters protein expression in malignant glioma tissue.	Carl Wibom	Ulrik Lassen Michael Bergqvist
16.55-17.15	The function of normal and mutated epidermal growth factor receptors in Glioblastoma Multiforme – establishment of an in vivo and in vitro model.	Marie-Thérèse Stockhausen	
17.15-17.30	General Discussion		
19.00	Dinner		

FRIDAY

09.00-15.00	SCIENTIFIC PROGRAMME	PRESENTER	CHAIRMAN
09.00-09.45	Lecture III Present for brain tumors. Future for brain tumors.	Hans Skovgaard Poulsen Roger Henriksson	
09.45-10.30	Lecture IV Stereotactic radiation: The neurosurgeon's view on facts and fiction.	Marianne Juhler	
10.30-11.00	Coffee break		
11.00-12.00	Session III Preclinical session.		
11.00-11.20	Glial progenitor marker NG2 promotes radio-resistance by elevated peroxiredoxin-1 resulting in rapid activation of the DNA damage response in Glioblastoma Multiforme.	Martha Chekenya	
11.20-11.40	Normal brain cells contribute to the bystander effect in lentiviral suicide gene therapy of malignant glioma.	Hrvoje Miletic	Helle Broholm Rolf Bjerkvig
11.40-12.00	Expression of the progenitor marker NG2 is dynamically regulated in glioma cell lines and correlates with chemoresistance.	Inger Anne Netland	
12.00-13.00	Lunch		
13.00-14.00	Session IV Clinical research		
13.00-13.20	Familial glioma- evidence for genetic causes and presentation of GLIOGENE consortium study.	Beatrice Malmer	
13.20-13.40	1p36 is a preferential target of chromosome 1 deletions in astrocytic tumors and homozygously deleted in a subset of glioblastomas.	Magnus Bäcklund	Knut Lote Hanna Mäenpää
13.40-14.00	Bevacizumab, a monoclonal antibody to the Vascular Endothelial Growth Factor (VEGF) and Irinotecan for treatment of recurrent primary malignant brain tumors in adults.	Benedikte Hasselbalch	
14.00-14.30	General Assembly		
14.30-15.00	Award for the best abstract Closing remarks By Hans Skovgaard Poulsen		